Stay updated with breaking news from Biofire Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The firm obtained FDA breakthrough device designation for an NGS approach to identify up to 400 bacterial pathogens used to diagnose sepsis and other bacterial infections.
COVID accelerated the development of cutting-edge PCR tests—and made the need for them urgent
Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.
The point-of-care molecular diagnostics market size to reach $5,381.18 million by 2028 from $2,230.94 million in 2021 to grow at a CAGR of 13.4% from 2021...
Clinical Comparison of Three Sample-to-Answer Systems for Detecting SARS-CoV-2 in B.1.1.7 Lineage Emergence